Foley Advises Upling in Launch of AI-Powered Cannabis Genetics Tool

Foley & Lardner LLP served as intellectual property and transactional counsel to Upling, the high-speed medical cannabis delivery app, in the launch of a new strain recommendation tool powered by artificial intelligence.

Foley assisted Upling with a provisional patent filing with the U.S. Patent and Trademark Office for the technology behind Bud-E, Upling’s groundbreaking, AI-powered cannabis genetics tool. Bud-E leverages patient-reported outcomes, medical history, and optional genetic information to generate personalized, science-based strain recommendations artificial intelligence. With Bud-E, Upling becomes one of the first cannabis delivery platforms to integrate advanced personalization technology directly into the user experience.

“Foley & Lardner has been a critical partner in launching Bud-E, seeing the vision and value of combining personal health data, patient feedback, and genetic insights as we work to transform cannabis from a trial-and-error process into one grounded in science,” said Colin Fraser, founder of Upling, the first Black-owned delivery-focused cannabis app. “Whether someone is managing PTSD, chronic pain, or insomnia, this tool takes the guesswork out and brings a precision medicine approach to cannabis care and I’m incredibly thankful for both their effort and collaboration. Coming on the heels of our recent TEDCO funding, this is a key moment for making progress in the ongoing campaign to deliver much needed medical care to people who need it most.” 

The Foley team was led by partners Von Bryant and Eric Sophir.